Aethlon Medical Announces Merger with North Immunology; ~$175M+ Financing

What Happened
Aethlon Medical, Inc. (AEMD) announced on September 17, 2026 that it entered into a definitive Agreement and Plan of Merger and Reorganization with North Immunology, Inc. The transaction contemplates a two-step merger structure (First Merger and Second Merger) intended to qualify as a tax-free reorganization under Section 368(a). Concurrent with signing, institutional and accredited investors agreed to purchase PIPE securities in a Private Placement totaling approximately $180 million (about $146M cash and ~$34M by converting North Immunology convertible notes); the Merger closing requires at least $175M in proceeds. Post-transaction, the combined company is expected to take the name “North Immunology, Inc.” and be led by North Immunology’s CEO.

Key Details

• Merger date/filed: Agreement signed Sept 17, 2026; outside termination date June 17, 2027 (subject to extensions).
• Valuation and ownership: North Immunology equity value contemplated at $150.0M (plus Private Placement proceeds) vs. Aethlon valuation of $16.5M; on a pro forma basis pre-Merger North Immunology holders expected to own ~95.25% and pre-Merger Aethlon holders ~4.75% of the combined company.
• Financing: Private Placement of ~ $180M (≈$146M cash + ≈$34M note conversions); closing of Merger conditioned on receipt of not less than $175M.
• Share mechanics and approvals: Exchange Ratio converts North Immunology securities into Aethlon common stock (with Pre-Funded Warrants where beneficial ownership limits would be exceeded); Aethlon will seek stockholder approval, file a Form S-4 (proxy/registration), pursue Nasdaq initial listing (may include a reverse stock split), and amend its charter (including name change).
• Other investor protections/events: Contingent Value Rights (CVRs) may be issued for holders of pre-Merger Aethlon shares to capture any future monetization proceeds from Aethlon’s legacy Hemopurifier assets; CVRs carry no voting rights and may pay nothing. Termination fees: Aethlon may owe $300k to North Immunology in certain terminations; North Immunology may owe $2.0M to Aethlon in certain terminations. Lock-ups: certain North Immunology stockholders agreed to 180-day post-closing lock-ups.

Why It Matters
This is a transformational deal for Aethlon: it brings in a large private financing and effectively replaces Aethlon’s current business mix with North Immunology’s assets and management. For Aethlon shareholders, the transaction will heavily dilute current equity (pro forma Aethlon holders ~4.75%) and requires shareholder and Nasdaq approvals, an effective S-4, and antitrust clearance before closing. The CVR structure preserves a potential (but uncertain) upside for any future proceeds from Aethlon’s legacy Hemopurifier business, but holders should note CVRs may pay nothing and carry no ownership or voting rights. Investors should watch upcoming filings (Form S-4, proxy materials), the Private Placement closing, Nasdaq initial listing progress, and the timing of the shareholder vote.